SCHEMBL6681574

SCHEMBL6681574

Cc1c2n(c(=O)n(Cc3ccc(F)c(F)c3)c1=O)C=C(C(=O)OCc1ccc(F)cc1)OC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
PKM P14618 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
LMNA P02545 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HTT P42858 2/20 0.33
KMT2A Q03164 2/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.33
MEN1 O00255 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
POLB P06746 1/20 0.33
MAPK14 Q16539 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6682041 0.86 MAPK14 (0.39) ALDH1A1TSHRMAPTKDM4ELMNA
SCHEMBL6679418 0.85 PTGDR2 (0.36) ALDH1A1TSHRKDM4EPTGDR2RAB9A
SCHEMBL6679240 0.84 TP53 (0.36) ALDH1A1TSHRTP53MAPTKDM4E
SCHEMBL6685075 0.84 TRPA1 (0.43) ALDH1A1TSHRTP53MAPTLMNA
SCHEMBL6683536 0.72 TRPA1 (0.45) ALDH1A1TP53MAPTKMT2AMEN1
SCHEMBL6679462 0.72 ALDH1A1 (0.36) ALDH1A1TSHRTP53KDM4EPTGDR2
SCHEMBL6679886 0.71 KDM4E (0.38) ALDH1A1TSHRMAPTKDM4ELMNA
SCHEMBL6682079 0.71 NOTUM (0.40) ALDH1A1TSHRKDM4EPKMLMNA
SCHEMBL6679307 0.70 TRPA1 (0.43) ALDH1A1TSHRTP53MAPTLMNA
SCHEMBL6680959 0.70 ALDH1A1 (0.38) ALDH1A1TSHRKDM4EPTGDR2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014354-A1 1,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors ROARK WILLIAM HOWARD (US) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034009-A1 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors MMP9, MMP13, MMP11 ALDH1A1 430/4885TSHR 4060/4885TP53 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.